



State of California-Health and Human Services Agency
Department of Health Services



ARNOLD SCHWARZENEGGER
Governor

November 30, 2006

CHDP Provider Information Notice No.: 06-13

TO: ALL CHILD HEALTH AND DISABILITY PREVENTION (CHDP)
PROGRAM PROVIDERS AND MEDI-CAL MANAGED CARE PLANS

SUBJECT: ADDITION OF HUMAN PAPILLOMAVIRUS (HPV) VACCINE AS A CHDP
BENEFIT, REPORTING CODES, REIMBURSEMENT FOR VACCINE
ADMINISTRATION, AND UPDATED CHDP VACCINE BENEFIT AND
REIMBURSEMENT TABLE

The purpose of this Provider Information Notice is to inform you that the HPV vaccine has been added as a CHDP program benefit.

This Information Notice provides the new CHDP administration code and billing and reimbursement information. An updated CHDP vaccine benefit and reimbursement table is enclosed that includes the addition of this new vaccine. A Vaccine for Children (VFC) Provider Letter is enclosed that contains additional information on the vaccine.

On June 8, 2006, the Food and Drug Administration approved HPV vaccine (Gardasil™), the first vaccine for cervical cancer prevention, for females' ages 9 to 26 years. Gardasil™, a quadrivalent vaccine, protects against four HPV types (6, 11, 16, 18), which are responsible for 70 percent of cervical cancers and 90 percent of genital warts. Annually, nearly 4000 women in the U.S. die from cervical cancer.

The Advisory Committee on Immunization Practices and the VFC Program issued a resolution on June 29, 2006, to add HPV vaccine to the VFC Program. The vaccine is given in 3 intramuscular injections over 6 months, with the second and third doses given 2 and 6 months after the first dose. The VFC Program will provide vaccine for females 9 through 18 years, with an emphasis on 11 to 12 year olds. A Vaccine Information Statement is available at <http://www.cdc.gov/nip/publications/VIS/vis-hpv.pdf>.

HPV vaccine can be given to females who have an equivocal Pap test, a positive Hybrid Capture II™ high risk test, or genital warts. Though data from clinical trials do not

indicate that the vaccine will have any therapeutic effect on existing Pap test abnormalities, HPV infection or genital warts, vaccination of these females would provide protection against infection with vaccine HPV types not already acquired.

HPV vaccine is contraindicated for females with a history of immediate hypersensitivity to yeast or to any vaccine component. The vaccine can be administered to females with minor acute illnesses, but should be deferred until after the illness improves for those with moderate or severe acute illnesses. HPV vaccine is not recommended for use in pregnancy.

HPV Vaccine as a CHDP Program Benefit

Effective November 1, 2006, CHDP will reimburse providers for the administration fee of HPV vaccine to CHDP eligible female children; the vaccine will be provided at no charge by the VFC Program for these children. The CHDP vaccine code is 76 and has the reimbursement rate of \$9.00 for the administration fee. This vaccine is not available for purchase at this time.

| | | | | |
|------------------------------------|----|-----|---------------------------------|--------|
| Human Papillomavirus (HPV) Vaccine | 76 | VFC | 9 years thru 18 years 11 months | \$9.00 |
|------------------------------------|----|-----|---------------------------------|--------|

Code 76 is payable for three doses. HPV vaccine can be administered at the same visit as other age-appropriate vaccines, such as Tetanus, Diphtheria, and Acellular Pertussis (Tdap) and Meningococcal Conjugate (MCV4) vaccines. HPV vaccine has been added to the Vaccine Codes and Rates Table found in the rates max CHDP section of the CHDP Provider Manual.

Reminder:

All CHDP program providers actively involved with immunized children must participate in the VFC Program, which provides vaccines at no cost to the provider for eligible children up to eighteen years eleven months. The CHDP Program reimburses only the immunization administration fee for VFC covered vaccines.

Billing Instructions for HPV Vaccine

Please use the following instructions for billing for HPV Vaccine. Refer to the CHDP Provider Manual for additional information.

- Enter the CHDP Code number, 76, and HPV on a blank line, under the immunization section of the PM 160 Confidential Screening/Billing Report.
- Enter a check mark in only one of the Immunization Outcome Columns (A or B) of the PM 160, as appropriate.
- Enter the administration fee in the Fees Column (Note: fees do not apply on the "Information Only" PM 160).
- If you have administered HPV vaccine on or after November 1, 2006, and prior to this notice, you are entitled to reimbursement for the administration of this vaccine. Please submit a PM 160 for the \$9.00 administration fee if you have not been previously reimbursed for the vaccine by any source.

CHDP Vaccine Benefits and Reimbursement Table

An updated CHDP Vaccine Benefit and Reimbursement Table are enclosed; it is dated November 1, 2006. The table includes the HPV vaccine code and reimbursement rate.

Your continuing participation in the CHDP Program is greatly appreciated. If you have any questions about CHDP vaccine benefits or other CHDP issues, please contact your local CHDP program office.

Original Signed by Marian Dalsey, M.D., M.P.H.

Marian Dalsey, M.D., M.P.H., Chief
Children's Medical Services Branch

Enclosures